[6-K] Defi Technologies, Inc. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

CalciMedica (CALC) Form 4: CEO, Director and 10% owner Rachel A. Leheny reported an open-market purchase on 07/21/2025. Through the Scheibler-Leheny Family Living Trust she bought 1,000 common shares at $3.40 (transaction code P), raising the trust’s stake to 3,500 shares.

After the transaction Leheny’s total reported beneficial ownership equals:

• 130,926 shares held directly
• 3,500 via family trust
• 1,000 by spouse
• 356,989 via Valence Investments SPV IV
• 66,228 via Valence Investments SPV V
• 316,109 via Valence Investments SPV VI

This aggregates to roughly 875k shares, reaffirming significant insider alignment. No derivative transactions were reported.

Insights

Senior Equity Analyst

TL;DR: CEO bought 1k shares at $3.40, small size but reinforces insider confidence; modestly positive signal.

The purchase is immaterial in size (<$4k) relative to Leheny’s existing ~875k-share position, yet any acquisition by a CEO who is already a 10% holder suggests continued belief in CALC’s prospects. No sales or derivative exercises accompanied the trade, so the directional signal is clean. While unlikely to move the valuation by itself, such activity can support sentiment for small-cap biotech investors monitoring insider alignment.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2025.

Commission File Number 001-41056

DEFI TECHNOLOGIES INC.

(Translation of registrant’s name into English)

Suite 2400, 333 Bay Street, Toronto, Ontario, Canada M5H 2T6 

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F                  ☒ Form 40-F

EXHIBIT INDEX

Exhibit Number		Description
99.1		New Release dated July 21, 2025 - DeFi Technologies Announces Commencement of Options Trading on Nasdaq

		DEFI TECHNOLOGIES INC.
		(Registrant)
Date: July 21, 2025	By	/s/ Kenny Choi
		Kenny Choi Corporate Secretary

FAQ

How many CALC shares did CEO Rachel Leheny buy on 07/21/2025?

She bought 1,000 common shares at $3.40 through her family trust.

What is Rachel Leheny’s total reported ownership in CalciMedica after the trade?

Her filings list roughly 875,000 shares across direct, trust, spouse and SPV holdings.

Was the Form 4 transaction a purchase or a sale?

It was a purchase (transaction code P) of common stock.

Did the Form 4 include any option or warrant activity?

No; Table II shows no derivative securities acquired or disposed.

Why is insider buying considered positive for CALC investors?

Purchases by senior insiders often signal confidence in the company’s outlook and align management’s interests with shareholders.